CureVac announces positive Phase II Covid-19 vaccine Covid-19 vaccine trial data

2024-01-08

疫苗临床结果临床2期信使RNA临床3期

CureVac announces positive Phase II Covid-19 vaccine trial data

Preview

来源: Pharmaceutical Technology

CureVac entered into a collaboration with GSK in 2020 to develop mRNA vaccines, specifying Covid-19 in 2021. Credit: IMAGINESTOCK via Getty Images.

Germany-based biopharmaceutical company Curevac has announced positive interim data from the Phase II study evaluating its Covid-19 mRNA vaccine candidates.

The monovalent vaccine CV0601 showed a 5.0-fold increase in neutralising antibodies against the Omicron BA/4-5 variant on day 29 post-booster when administered at a medium dose, surpassing the comparator vaccine’s 3.6-fold ratio.

For the bivalent vaccine CV0701, which was tested at low, medium, and high doses, the post-booster neutralising antibody titres were 2.7-fold, 3.7-fold, and 4.6-fold higher than pre-booster levels on day 29, respectively. The comparator vaccine showed a 3.6-fold ratio of post-booster to pre-booster titers.

The randomised, active-controlled, observer-blind study (NCT05960097) enrolled 427 participants and evaluated monovalent CV0601 and bivalent CV0701 vaccines against Omicron BA.4-5 variant and original SARS-CoV-2.

Both vaccines, which are developed in partnership with GSK, were compared to a licensed bivalent mRNA-based Covid-19 vaccine Covid-19 vaccine.

The head-to-head study demonstrated well-tolerated reactogenicity for both candidates. All three tested dose levels were lower than the ones used in mRNA-based Covid-19 vaccines Covid-19 vaccines licensed in the US and Europe.

CureVac is now discussing the next steps with regulatory authorities, including a Phase III study.

In the announcement accompanying the results, CureVac chief development officer Myriam Mendila said: “We are greatly encouraged by the strong immunogenicity results achieved for our Covid-19 mRNA vaccine candidates and are in advanced discussions with regulatory authorities to determine the best path forward for a pivotal Phase III study.”

CureVac and pharma-giant GSK dosed the first subject in the study in August 2023.

CureVac and GSK are also continuing to advance their joint flu vaccine programme, as highlighted in the announcement. In May 2023, GSK and CureVac dosed the first subject in the Phase I/II trial of its multivalent mRNA vaccine against four influenza strains. The influenza trial plans to enrol 1512 healthy adults and has an estimated completion date of June 2024.

CureVac hit a setback in June 2021 when its Covid-19 vaccine Covid-19 vaccine failed to meet Phase IIb/III prespecified efficacy criteria. The trial was carried out in partnership with Bayer and enrolled 40,000 subjects across ten countries.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

CureVac NV